Answers are grounded in this paper and cite their sources.
Unlike dermatomyositis, which is widely linked to malignancy, systemic sclerosis is rarely recognized as a paraneoplastic condition in everyday practice, largely due to a lack of clinical awareness regarding this emerging concept. However, mounting pathophysiological and epidemiological data suggest that systemic sclerosis may represent a putative paraneoplastic syndrome, particularly in the anti-RNA polymerase III-positive subset. We report the case of a 58-year-old female who, one month after being diagnosed with metastatic high-grade serous ovarian carcinoma (FIGO stage IIIC), developed Raynaud's phenomenon, which rapidly progressed over the following four months to sclerodactyly, cutaneous sclerosis of the dorsum of both hands and forearms, facial telangiectasias, and microstomia. Nailfold capillaroscopy demonstrated devascularization and mild capillary ectasia. Laboratory evaluation demonstrated a positive antinuclear antibody (ANA) titer (1:640) with a fine speckled nuclear pattern and high-titer anti-RNA polymerase III (anti-RNAP III) antibodies (212 U/mL), the autoantibody most strongly linked to paraneoplastic systemic sclerosis. The patient fulfilled 17 points on the 2013 ACR/EULAR classification criteria for systemic sclerosis. She underwent neoadjuvant chemotherapy, cytoreductive surgery, and maintenance therapy with niraparib. Following antineoplastic treatment, the patient experienced clinically significant improvement in cutaneous sclerosis without evidence of pulmonary or renal progression of systemic sclerosis. This report describes an unusual presentation of paraneoplastic systemic sclerosis associated with high-grade serous ovarian carcinoma, an uncommon association, as breast and lung cancers are the malignancies most frequently linked to systemic sclerosis. Furthermore, it reinforces the necessity of maintaining a high index of suspicion for underlying occult malignancies in patients presenting with recent-onset systemic sclerosis and anti-RNAP III positivity.
No takes yet. Share an insight, caveat, or question.
Miyazima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: